PE20240768A1 - Combinaciones de pristinamicina ia y flopristin para el tratamiento o prevencion de infecciones bacterianas - Google Patents
Combinaciones de pristinamicina ia y flopristin para el tratamiento o prevencion de infecciones bacterianasInfo
- Publication number
- PE20240768A1 PE20240768A1 PE2023003141A PE2023003141A PE20240768A1 PE 20240768 A1 PE20240768 A1 PE 20240768A1 PE 2023003141 A PE2023003141 A PE 2023003141A PE 2023003141 A PE2023003141 A PE 2023003141A PE 20240768 A1 PE20240768 A1 PE 20240768A1
- Authority
- PE
- Peru
- Prior art keywords
- spp
- flopristin
- pristinamycin
- relates
- bacterial infections
- Prior art date
Links
- 108010015795 Streptogramin B Proteins 0.000 title abstract 6
- YGXCETJZBDTKRY-DZCVGBHJSA-N pristinamycin IA Chemical compound N([C@@H]1C(=O)N[C@@H](C(N2CCC[C@H]2C(=O)N(C)[C@@H](CC=2C=CC(=CC=2)N(C)C)C(=O)N2CCC(=O)C[C@H]2C(=O)N[C@H](C(=O)O[C@@H]1C)C=1C=CC=CC=1)=O)CC)C(=O)C1=NC=CC=C1O YGXCETJZBDTKRY-DZCVGBHJSA-N 0.000 title abstract 6
- YGXCETJZBDTKRY-UHFFFAOYSA-N Pristinamycin Component I A Natural products CC1OC(=O)C(C=2C=CC=CC=2)NC(=O)C2CC(=O)CCN2C(=O)C(CC=2C=CC(=CC=2)N(C)C)N(C)C(=O)C2CCCN2C(=O)C(CC)NC(=O)C1NC(=O)C1=NC=CC=C1O YGXCETJZBDTKRY-UHFFFAOYSA-N 0.000 title abstract 5
- DFSJQGCLWZVMOD-IQIMCDJDSA-N flopristin Chemical compound C1[C@H](F)C[C@H](O)\C=C(/C)\C=C\CNC(=O)\C=C\[C@@H](C)[C@@H](C(C)C)OC(=O)[C@H]2CCCN2C(=O)C2=COC1=N2 DFSJQGCLWZVMOD-IQIMCDJDSA-N 0.000 title abstract 4
- 229950011406 flopristin Drugs 0.000 title abstract 4
- 208000035143 Bacterial infection Diseases 0.000 title abstract 2
- 208000022362 bacterial infectious disease Diseases 0.000 title abstract 2
- 230000002265 prevention Effects 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 241000193830 Bacillus <bacterium> Species 0.000 abstract 1
- 241000606161 Chlamydia Species 0.000 abstract 1
- 241000194033 Enterococcus Species 0.000 abstract 1
- 241000589601 Francisella Species 0.000 abstract 1
- 241000207202 Gardnerella Species 0.000 abstract 1
- 241000606790 Haemophilus Species 0.000 abstract 1
- 241000589248 Legionella Species 0.000 abstract 1
- 208000007764 Legionnaires' Disease Diseases 0.000 abstract 1
- 241000588621 Moraxella Species 0.000 abstract 1
- 241000204031 Mycoplasma Species 0.000 abstract 1
- 241000588653 Neisseria Species 0.000 abstract 1
- 241000191940 Staphylococcus Species 0.000 abstract 1
- 241000194017 Streptococcus Species 0.000 abstract 1
- 108010015791 Streptogramin A Proteins 0.000 abstract 1
- 108010034396 Streptogramins Proteins 0.000 abstract 1
- 241000202898 Ureaplasma Species 0.000 abstract 1
- 230000000844 anti-bacterial effect Effects 0.000 abstract 1
- 230000001580 bacterial effect Effects 0.000 abstract 1
- 230000003115 biocidal effect Effects 0.000 abstract 1
- -1 flopristin) Chemical compound 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- DAIKHDNSXMZDCU-FQTGFAPKSA-N pristinamycin IIA Chemical compound C1C(=O)C[C@H](O)\C=C(/C)\C=C\CNC(=O)\C=C\[C@@H](C)[C@@H](C(C)C)OC(=O)C2=CCCN2C(=O)C2=COC1=N2 DAIKHDNSXMZDCU-FQTGFAPKSA-N 0.000 abstract 1
- DAIKHDNSXMZDCU-OUDXUNEISA-N pristinamycin-IIA Natural products CC(C)[C@H]1OC(=O)C2=CCCN2C(=O)c3coc(CC(=O)C[C@H](O)C=C(C)C=CCNC(=O)C=C[C@@H]1C)n3 DAIKHDNSXMZDCU-OUDXUNEISA-N 0.000 abstract 1
- 241000894007 species Species 0.000 abstract 1
- 229940041030 streptogramins Drugs 0.000 abstract 1
- 230000002195 synergetic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/15—Depsipeptides; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/424—Oxazoles condensed with heterocyclic ring systems, e.g. clavulanic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
La presente invencion se refiere a composiciones antibioticas que comprenden diversas proporciones de dos estreptograminas, estreptogramina B (por ejemplo, pristinamicina IA) y estreptogramina A (por ejemplo, flopristina), que poseen actividades antibacterianas sinergicas contra Staphylococcus spp., Streptococcus spp., Enterococcus spp., Haemophilus spp., Moraxella spp., Legionella spp., Chlamydia spp., Mycoplasma spp., Ureaplasma spp., Neisseria spp., Gardnerella spp., Bacillus spp., y Francisella spp. asi como otras especies bacterianas. En particular, la invencion se refiere a composiciones farmaceuticas que comprenden pristinamicina IA (PIA) o una sal farmaceuticamente aceptable de la misma y flopristina o una sal farmaceuticamente aceptable de la misma, en la que la proporcion en peso de PIA:flopristina varia de aproximadamente 1:99 a aproximadamente 99:1. Ademas, la invencion se refiere a composiciones farmaceuticas y metodos para tratar y prevenir una variedad de infecciones bacterianas.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163192564P | 2021-05-24 | 2021-05-24 | |
| PCT/US2022/030552 WO2022251118A1 (en) | 2021-05-24 | 2022-05-23 | Pristinamycin ia and flopristin combinations in treating or preventing bacterial infections |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20240768A1 true PE20240768A1 (es) | 2024-04-17 |
Family
ID=84229173
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2023003141A PE20240768A1 (es) | 2021-05-24 | 2022-05-23 | Combinaciones de pristinamicina ia y flopristin para el tratamiento o prevencion de infecciones bacterianas |
Country Status (12)
| Country | Link |
|---|---|
| EP (1) | EP4346799A1 (es) |
| JP (1) | JP2024521147A (es) |
| KR (1) | KR20240011728A (es) |
| CN (1) | CN117529312A (es) |
| AU (1) | AU2022283200A1 (es) |
| BR (1) | BR112023024376A2 (es) |
| CA (1) | CA3221564A1 (es) |
| CO (1) | CO2023016560A2 (es) |
| IL (1) | IL308757A (es) |
| PE (1) | PE20240768A1 (es) |
| TW (1) | TW202313024A (es) |
| WO (1) | WO2022251118A1 (es) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024112631A1 (en) * | 2022-11-22 | 2024-05-30 | Aimmax Therapeutics, Inc. | Streptogramin a monotherapy for treating or preventing bacterial infections |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0821913D0 (en) * | 2008-12-02 | 2009-01-07 | Price & Co | Antibacterial compounds |
| CA2910756C (en) * | 2013-05-01 | 2021-11-16 | Neoculi Pty Ltd | Compounds and methods of treating infections |
-
2022
- 2022-05-23 EP EP22811921.0A patent/EP4346799A1/en active Pending
- 2022-05-23 CA CA3221564A patent/CA3221564A1/en active Pending
- 2022-05-23 KR KR1020237042206A patent/KR20240011728A/ko unknown
- 2022-05-23 WO PCT/US2022/030552 patent/WO2022251118A1/en active Application Filing
- 2022-05-23 AU AU2022283200A patent/AU2022283200A1/en active Pending
- 2022-05-23 JP JP2023572516A patent/JP2024521147A/ja active Pending
- 2022-05-23 IL IL308757A patent/IL308757A/en unknown
- 2022-05-23 CN CN202280037370.5A patent/CN117529312A/zh active Pending
- 2022-05-23 PE PE2023003141A patent/PE20240768A1/es unknown
- 2022-05-23 BR BR112023024376A patent/BR112023024376A2/pt unknown
- 2022-05-24 TW TW111119273A patent/TW202313024A/zh unknown
-
2023
- 2023-11-30 CO CONC2023/0016560A patent/CO2023016560A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| TW202313024A (zh) | 2023-04-01 |
| WO2022251118A1 (en) | 2022-12-01 |
| AU2022283200A1 (en) | 2023-11-23 |
| CA3221564A1 (en) | 2022-12-01 |
| IL308757A (en) | 2024-01-01 |
| EP4346799A1 (en) | 2024-04-10 |
| CN117529312A (zh) | 2024-02-06 |
| JP2024521147A (ja) | 2024-05-28 |
| CO2023016560A2 (es) | 2023-12-11 |
| BR112023024376A2 (pt) | 2024-02-15 |
| KR20240011728A (ko) | 2024-01-26 |
| WO2022251118A9 (en) | 2023-01-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Miladi et al. | Synergistic effect of eugenol, carvacrol, thymol, p-cymene and γ-terpinene on inhibition of drug resistance and biofilm formation of oral bacteria | |
| Albano et al. | Antibacterial and anti-biofilm activities of cinnamaldehyde against S. epidermidis | |
| Al Atya et al. | Anti-MRSA activities of enterocins DD28 and DD93 and evidences on their role in the inhibition of biofilm formation | |
| CO2023016560A2 (es) | Combinaciones de pristinamicina ia y flopristin para el tratamiento o prevención de infecciones bacterianas | |
| Kelesidis et al. | Combination therapy with daptomycin, linezolid, and rifampin as treatment option for MRSA meningitis and bacteremia | |
| Khameneh et al. | Combination of anti-tuberculosis drugs with vitamin C or NAC against different Staphylococcus aureus and Mycobacterium tuberculosis strains | |
| BRPI1008663B8 (pt) | bacteriófago com um genoma, composição farmacêutica, uso de uma quantidade terapeuticamente eficaz da composição farmacêutica, método de diagnóstico do agente causador de uma infecção bacteriana e uso do bacteriófago | |
| IL235526B2 (en) | Prevention, disruption and treatment of biofilm with bacteriophage lysin | |
| RU2014149351A (ru) | Комбинации лизина бактериофага и антибиотика против грам-положительных бактерий | |
| CA3067542A1 (en) | Bacitracin and/or daptomycin combined with cannabidiol for treatment of bacterial infections | |
| Shin et al. | In vitro inhibitory activities of essential oils from two Korean Thymus species against antibiotic-resistant pathogens | |
| NZ591051A (en) | C7-fluoro substituted tetracycline compounds | |
| Oh et al. | Antioxidant-based synergistic eradication of methicillin-resistant Staphylococcus aureus (MRSA) biofilms with bacitracin | |
| RU2011130278A (ru) | Новые противобактериальные средства для лечения грамположительных инфекций | |
| BRPI0916885B8 (pt) | composição farmacêutica | |
| Fan et al. | Antibacterial activity of the recombinant antimicrobial peptide Ib-AMP4 from Impatiens balsamina and its synergy with other antimicrobial agents against drug resistant bacteria | |
| Huang et al. | Comparative bactericidal activities of daptomycin, glycopeptides, linezolid and tigecycline against blood isolates of Gram-positive bacteria in Taiwan | |
| Mahboobi et al. | Bactericidal effects of essential oils from clove, lavender and geranium on multi-drug resistant isolates of Pseudomonas aeruginosa | |
| Oliveira et al. | Influence of papain in biofilm formed by methicillin-resistant Staphylococcus epidermidis and methicillin-resistant Staphylococcus haemolyticus isolates | |
| Brauers et al. | Bactericidal activity of daptomycin, vancomycin, teicoplanin and linezolid against Staphylococcus aureus, Enterococcus faecalis and Enterococcus faecium using human peak free serum drug concentrations | |
| Baishya et al. | Establishment of a simple reproducible model for antibiotic sensitivity pattern study of biofilm forming Staphylococcus aureus | |
| Delpech et al. | An in vitro evaluation of the efficacy of tedizolid: implications for the treatment of skin and soft tissue infections | |
| CY1110971T1 (el) | Τοπικη αντιβιοτικη συνθεση για την προληψη της νοσου lyme | |
| Hassanshahian et al. | The antimicrobial effects of the alcoholic extracts of pomegranate (punica granatum) on the planktonic forms and biofilm structures of six pathogenic bacteria | |
| CL2021003317A1 (es) | Medicamento y uso del mismo para tratar infecciones bacterianas que involucran una biopelícula. |